You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePropafenone
Accession NumberDB01182  (APRD00261)
TypeSmall Molecule
GroupsApproved
DescriptionAn antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. [PubChem]
Structure
Thumb
Synonyms
1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone
2-(2'-Hydroxy-3'-propylaminopropoxy)-omega-phenylpropiophenone
Propafenona
Propafenonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Myl-propafenoneTablet150 mgOralMylan Pharmaceuticals Ulc2002-03-08Not applicableCanada
Myl-propafenoneTablet300 mgOralMylan Pharmaceuticals Ulc2002-03-08Not applicableCanada
Mylan-propafenoneTablet300 mgOralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-propafenoneTablet150 mgOralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Nu-propafenoneTablet150 mgOralNu Pharm IncNot applicableNot applicableCanada
PMS-propafenoneTablet300 mgOralPharmascience Inc2001-04-09Not applicableCanada
PMS-propafenoneTablet150 mgOralPharmascience Inc2008-02-22Not applicableCanada
PMS-propafenoneTablet300 mgOralPharmascience Inc2008-02-22Not applicableCanada
PMS-propafenoneTablet150 mgOralPharmascience Inc2001-04-09Not applicableCanada
PropafenoneTablet300 mgOralSanis Health Inc2010-02-16Not applicableCanada
PropafenoneTablet150 mgOralSanis Health Inc2010-02-16Not applicableCanada
Propafenone Hydrochloride SRCapsule, extended release325 mg/1OralPrasco Laboratories2014-10-22Not applicableUs
Propafenone Hydrochloride SRCapsule, extended release425 mg/1OralPrasco Laboratories2014-10-22Not applicableUs
Propafenone Hydrochloride SRCapsule, extended release225 mg/1OralPrasco Laboratories2014-10-22Not applicableUs
Propafenone-150Tablet150 mgOralPro Doc Limitee2008-03-072016-07-18Canada
Propafenone-300Tablet300 mgOralPro Doc Limitee2009-05-262016-07-18Canada
RythmolTablet, film coated225 mg/1OralGlaxo Smith Kline Llc2010-01-04Not applicableUs
RythmolTablet300 mgOralBgp Pharma Ulc1988-12-31Not applicableCanada
RythmolTablet, film coated150 mg/1OralGlaxo Smith Kline Llc2010-01-042017-05-31Us
RythmolTablet150 mgOralBgp Pharma Ulc1988-12-31Not applicableCanada
Rythmol SRCapsule, extended release225 mg/1OralGlaxo Smith Kline Llc2011-03-17Not applicableUs
Rythmol SRCapsule, extended release325 mg/1OralGlaxo Smith Kline Llc2011-03-17Not applicableUs
Rythmol SRCapsule, extended release425 mg/1OralGlaxo Smith Kline Llc2011-03-17Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-propafenoneTablet300 mgOralApotex Inc2001-02-22Not applicableCanada
Apo-propafenoneTablet150 mgOralApotex Inc2001-02-22Not applicableCanada
PropafenoneCapsule, extended release325 mg/1OralRebel Distributors Corp2011-01-03Not applicableUs
Propafenone HClTablet, film coated150 mg/1OralAmerican Health Packaging2012-05-01Not applicableUs
Propafenone HClTablet, film coated150 mg/1OralActavis Pharma, Inc.2000-10-24Not applicableUs
Propafenone HClTablet, film coated225 mg/1OralActavis Pharma, Inc.2000-10-24Not applicableUs
Propafenone HClTablet, film coated150 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-09-10Not applicableUs
Propafenone HClTablet, film coated225 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-09-10Not applicableUs
Propafenone HClTablet, film coated225 mg/1OralAvera Mc Kennan Hospital2015-10-01Not applicableUs
Propafenone HydrochlorideCapsule, extended release425 mg/1OralPar Pharmaceutical, Inc.2011-01-03Not applicableUs
Propafenone HydrochlorideCapsule, extended release225 mg/1OralMylan Pharmaceuticals Inc.2016-05-23Not applicableUs
Propafenone HydrochlorideCapsule, extended release225 1/1OralAmerican Health Packaging2015-10-01Not applicableUs
Propafenone HydrochlorideTablet, film coated300 mg/1OralMutual Pharmaceutical Co., Inc.2001-11-29Not applicableUs
Propafenone HydrochlorideCapsule, extended release225 mg/1OralGolden State Medical Supply, Inc.2015-09-15Not applicableUs
Propafenone HydrochlorideTablet, film coated225 mg/1OralA S Medication Solutions2002-10-17Not applicableUs
Propafenone HydrochlorideCapsule, extended release225 mg/1OralPar Pharmaceutical, Inc.2011-01-03Not applicableUs
Propafenone HydrochlorideTablet, film coated150 mg/1Oralbryant ranch prepack2002-10-17Not applicableUs
Propafenone HydrochlorideTablet, film coated150 mg/1OralQualitest Pharmaceuticals2002-10-17Not applicableUs
Propafenone HydrochlorideTablet, film coated150 mg/1OralMylan Institutional Inc.2003-02-01Not applicableUs
Propafenone HydrochlorideCapsule, extended release225 mg/1OralAmerican Health Packaging2014-10-20Not applicableUs
Propafenone HydrochlorideCapsule, extended release325 mg/1OralMylan Pharmaceuticals Inc.2016-05-23Not applicableUs
Propafenone HydrochlorideTablet, coated150 mg/1OralANI Pharmaceuticals, Inc.2015-03-31Not applicableUs
Propafenone HydrochlorideCapsule, extended release225 mg/1OralAv Kare, Inc.2016-01-21Not applicableUs
Propafenone HydrochlorideTablet, film coated150 mg/1OralPhysicians Total Care, Inc.2005-05-18Not applicableUs
Propafenone HydrochlorideCapsule, extended release325 mg/1OralGolden State Medical Supply, Inc.2015-09-15Not applicableUs
Propafenone HydrochlorideCapsule, extended release225 mg/1OralActavis Pharma, Inc.2015-10-15Not applicableUs
Propafenone HydrochlorideCapsule, extended release225 1/1OralPar Pharmaceutical, Inc.2011-01-03Not applicableUs
Propafenone HydrochlorideTablet, film coated225 mg/1OralQualitest Pharmaceuticals2002-10-17Not applicableUs
Propafenone HydrochlorideTablet, film coated150 mg/1OralMutual Pharmaceutical Co., Inc.2001-11-29Not applicableUs
Propafenone HydrochlorideCapsule, extended release325 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Propafenone HydrochlorideCapsule, extended release425 mg/1OralMylan Pharmaceuticals Inc.2016-05-23Not applicableUs
Propafenone HydrochlorideCapsule, extended release325 mg/1OralAv Kare, Inc.2016-01-21Not applicableUs
Propafenone HydrochlorideTablet, film coated150 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-10-17Not applicableUs
Propafenone HydrochlorideTablet, coated225 mg/1OralANI Pharmaceuticals, Inc.2015-03-31Not applicableUs
Propafenone HydrochlorideTablet, film coated225 mg/1OralPhysicians Total Care, Inc.2008-10-09Not applicableUs
Propafenone HydrochlorideCapsule, extended release425 mg/1OralGolden State Medical Supply, Inc.2015-09-15Not applicableUs
Propafenone HydrochlorideCapsule, extended release325 mg/1OralActavis Pharma, Inc.2015-10-15Not applicableUs
Propafenone HydrochlorideCapsule, extended release325 mg/1OralPar Pharmaceutical, Inc.2011-01-03Not applicableUs
Propafenone HydrochlorideTablet, film coated300 mg/1OralQualitest Pharmaceuticals2002-10-17Not applicableUs
Propafenone HydrochlorideTablet, film coated225 mg/1OralA S Medication Solutions2002-10-17Not applicableUs
Propafenone HydrochlorideTablet, film coated225 mg/1OralMutual Pharmaceutical Co., Inc.2001-11-29Not applicableUs
Propafenone HydrochlorideTablet, coated300 mg/1OralANI Pharmaceuticals, Inc.2015-03-31Not applicableUs
Propafenone HydrochlorideCapsule, extended release425 mg/1OralAv Kare, Inc.2016-01-21Not applicableUs
Propafenone HydrochlorideTablet, film coated150 mg/1OralCardinal Health2011-05-20Not applicableUs
Propafenone HydrochlorideCapsule, extended release425 mg/1OralActavis Pharma, Inc.2015-10-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Propafenone hydrochloride
34183-22-7
Thumb
  • InChI Key: XWIHRGFIPXWGEF-UHFFFAOYNA-N
  • Monoisotopic Mass: 377.175771474
  • Average Mass: 377.905
DBSALT000148
Categories
UNII68IQX3T69U
CAS number54063-53-5
WeightAverage: 341.444
Monoisotopic: 341.199093735
Chemical FormulaC21H27NO3
InChI KeyJWHAUXFOSRPERK-UHFFFAOYSA-N
InChI
InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3
IUPAC Name
1-{2-[2-hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one
SMILES
CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1
Pharmacology
IndicationUsed to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia.
Structured Indications
PharmacodynamicsPropafenone is a Class 1C antiarrhythmic drug with local anesthetic effects, and a direct stabilizing action on myocardial membranes. It is used in the treatment of atrial and ventricular arrhythmias. It works by slowing the influx of sodium ions into the cardiac muscle cells, causing a decrease in excitablity of the cells. Propafenone has local anesthetic activity approximately equal to procaine.
Mechanism of actionThe electrophysiological effect of propafenone manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions, which is responsible for the drugs antiarrhythmic actions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity. At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium channel protein type 5 subunit alphaProteinyes
inhibitor
HumanQ14524 details
Potassium voltage-gated channel subfamily H member 2Proteinyes
inhibitor
HumanQ12809 details
Related Articles
AbsorptionNearly completely absorbed following oral administration (90%). Systemic bioavailability ranges from 5 to 50%, due to significant first-pass metabolism. This wide range in systemic bioavailability is related to two factors: presence of food (food increases bioavailability) and dosage (bioavailability is 3.4% for a 150-mg tablet compared to 10.6% for a 300-mg tablet).
Volume of distribution
  • 252 L
Protein binding97%
Metabolism

Metabolized primarily in the liver where it is rapidly and extensively metabolized to two active metabolites, 5-hydroxypropafenone and N-depropylpropafenone. These metabolites have antiarrhythmic activity comparable to propafenone but are present in concentrations less than 25% of propafenone concentrations.

SubstrateEnzymesProduct
Propafenone
N-desalkylpropafenoneDetails
Propafenone
5-hydroxypropafenoneDetails
Propafenone
Not Available
N-depropylpropafenoneDetails
Route of eliminationApproximately 50% of propafenone metabolites are excreted in the urine following administration of immediate release tablets.
Half life2-10 hours
ClearanceNot Available
ToxicitySymptoms of propafenone overdose (usually most severe within the first 3 hours) may include convulsions (rarely), heartbeat irregularities, low blood pressure, and sleepiness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Propafenone can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Propafenone.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Propafenone.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Propafenone.Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Propafenone.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Propafenone.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Propafenone.Approved
AjmalinePropafenone may increase the arrhythmogenic activities of Ajmaline.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Propafenone.Experimental
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Propafenone.Approved, Investigational
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Propafenone.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Propafenone.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Propafenone.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Propafenone.Experimental
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Propafenone.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Propafenone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Propafenone.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Propafenone.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Propafenone.Approved
AnagrelidePropafenone may increase the QTc-prolonging activities of Anagrelide.Approved
AnvirzelThe serum concentration of Anvirzel can be increased when it is combined with Propafenone.Investigational
Aop200704The serum concentration of Aop200704 can be increased when it is combined with Propafenone.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Propafenone.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
AprepitantThe serum concentration of Propafenone can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Propafenone.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Propafenone.Approved
Arsenic trioxidePropafenone may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be increased when it is combined with Propafenone.Approved
AsenapinePropafenone may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe serum concentration of Propafenone can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Propafenone.Approved
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Propafenone.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Propafenone.Approved, Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Propafenone.Approved
BedaquilinePropafenone may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololThe serum concentration of Befunolol can be increased when it is combined with Propafenone.Experimental
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Propafenone.Approved
BeractantPropafenone may increase the bradycardic activities of Beractant.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Propafenone.Approved, Vet Approved
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Propafenone.Approved
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Propafenone.Approved
BexaroteneThe serum concentration of Propafenone can be decreased when it is combined with Bexarotene.Approved, Investigational
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Propafenone.Approved
BoceprevirThe serum concentration of Propafenone can be increased when it is combined with Boceprevir.Approved
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Propafenone.Approved
BortezomibThe serum concentration of Propafenone can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Propafenone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Propafenone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Propafenone.Approved
BretyliumBretylium may increase the bradycardic activities of Propafenone.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Propafenone.Approved, Investigational
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Propafenone.Investigational
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Propafenone.Experimental, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Propafenone.Approved
BupropionThe serum concentration of Propafenone can be increased when it is combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Propafenone.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Propafenone.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Propafenone.Approved
CalfactantPropafenone may increase the bradycardic activities of Calfactant.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Propafenone.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Propafenone.Approved
CarbamazepineThe serum concentration of Propafenone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Propafenone.Approved
CarteololThe serum concentration of Carteolol can be increased when it is combined with Propafenone.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Propafenone.Approved, Investigational
CelecoxibThe serum concentration of Celecoxib can be increased when it is combined with Propafenone.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Propafenone.Approved, Investigational
CeritinibPropafenone may increase the bradycardic activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Propafenone.Withdrawn
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Propafenone.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Propafenone.Approved, Vet Approved
CholecalciferolThe serum concentration of Cholecalciferol can be increased when it is combined with Propafenone.Approved, Nutraceutical
CimetidineThe serum concentration of Propafenone can be increased when it is combined with Cimetidine.Approved
CinacalcetThe serum concentration of Propafenone can be increased when it is combined with Cinacalcet.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
CisapridePropafenone may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Propafenone.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Propafenone.Approved
ClarithromycinThe serum concentration of Propafenone can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Clemastine can be increased when it is combined with Propafenone.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Propafenone.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Propafenone.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Propafenone.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Propafenone.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Propafenone.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Clotrimazole can be increased when it is combined with Propafenone.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Propafenone.Approved
CobicistatThe serum concentration of Cobicistat can be increased when it is combined with Propafenone.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Propafenone.Approved
CocaineThe serum concentration of Propafenone can be increased when it is combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Propafenone.Approved
ConivaptanThe serum concentration of Propafenone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Propafenone.Approved
CrizotinibThe serum concentration of Propafenone can be increased when it is combined with Crizotinib.Approved
CyclosporineThe serum concentration of Propafenone can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Propafenone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Propafenone.Approved
DabrafenibThe serum concentration of Propafenone can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Propafenone.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Propafenone.Approved
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Propafenone.Approved, Investigational
DarunavirThe serum concentration of Propafenone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Propafenone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Propafenone.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Propafenone.Approved
DeferasiroxThe serum concentration of Propafenone can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Propafenone.Approved
DelavirdineThe serum concentration of Propafenone can be increased when it is combined with Delavirdine.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Propafenone.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Propafenone.Approved
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Propafenone.Approved
DexamethasoneThe serum concentration of Propafenone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Propafenone.Approved, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Propafenone.Approved, Illicit, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Propafenone.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Propafenone.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Propafenone.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Propafenone.Approved
DihydroergotamineThe serum concentration of Propafenone can be increased when it is combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Propafenone.Illicit
DiltiazemThe serum concentration of Propafenone can be increased when it is combined with Diltiazem.Approved
DiphenhydramineThe serum concentration of Diphenhydramine can be increased when it is combined with Propafenone.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Propafenone.Approved
DisopyramidePropafenone may increase the arrhythmogenic activities of Disopyramide.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Propafenone.Approved, Investigational
DofetilidePropafenone may increase the arrhythmogenic activities of Dofetilide.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Propafenone.Approved
DomperidonePropafenone may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilDonepezil may increase the bradycardic activities of Propafenone.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Propafenone.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Propafenone.Approved, Investigational
DoxycyclineThe serum concentration of Propafenone can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaronePropafenone may increase the arrhythmogenic activities of Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Propafenone.Approved, Vet Approved
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Propafenone.Approved
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Propafenone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Propafenone.Approved
EfavirenzThe serum concentration of Propafenone can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Propafenone.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Propafenone.Approved
EnzalutamideThe serum concentration of Propafenone can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Propafenone.Approved, Investigational
EribulinEribulin may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Propafenone.Approved, Investigational
ErythromycinThe serum concentration of Propafenone can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramPropafenone may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Propafenone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe serum concentration of Esmolol can be increased when it is combined with Propafenone.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Propafenone.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Propafenone.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Propafenone.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Propafenone.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Propafenone.Withdrawn
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Propafenone.Approved
EtravirineThe serum concentration of Propafenone can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Propafenone.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Propafenone.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Propafenone.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Propafenone.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Propafenone.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propafenone.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Propafenone.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Propafenone.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
FlecainidePropafenone may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FluconazoleThe serum concentration of Propafenone can be increased when it is combined with Fluconazole.Approved
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Propafenone.Investigational
FluoxetinePropafenone may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolPropafenone may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Propafenone.Approved
FluvoxamineThe serum concentration of Propafenone can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
FosamprenavirThe serum concentration of Propafenone can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Propafenone can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Propafenone.Approved
FosphenytoinThe serum concentration of Propafenone can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Propafenone can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Propafenone.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Propafenone.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Propafenone.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Propafenone.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
GoserelinGoserelin may increase the QTc-prolonging activities of Propafenone.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Propafenone.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Propafenone.Withdrawn
GuanfacineGuanfacine may increase the bradycardic activities of Propafenone.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Propafenone.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Propafenone.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Propafenone.Approved, Vet Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Propafenone.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Propafenone.Approved
IbutilidePropafenone may increase the arrhythmogenic activities of Ibutilide.Approved
IdelalisibThe serum concentration of Propafenone can be increased when it is combined with Idelalisib.Approved
IloperidonePropafenone may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Propafenone can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Propafenone.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Propafenone.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Propafenone.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Propafenone.Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Propafenone.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Propafenone.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Propafenone.Approved, Investigational
IsavuconazoniumThe serum concentration of Propafenone can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Propafenone.Approved, Vet Approved
IsoniazidThe serum concentration of Isoniazid can be increased when it is combined with Propafenone.Approved
IsradipineThe serum concentration of Propafenone can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Propafenone can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Propafenone.Approved
IvacaftorThe serum concentration of Propafenone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Propafenone.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Propafenone.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Propafenone.Approved, Investigational
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Propafenone.Approved
LacosamidePropafenone may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Propafenone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Propafenone.Approved, Investigational
LanreotidePropafenone may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Propafenone.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Propafenone.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Propafenone.Approved
LenvatinibPropafenone may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Propafenone.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Propafenone.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Propafenone.Approved
LidocaineThe metabolism of Propafenone can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Propafenone.Approved
LithiumLithium may increase the QTc-prolonging activities of Propafenone.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Propafenone.Approved
LopinavirThe serum concentration of Propafenone can be increased when it is combined with Lopinavir.Approved
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Propafenone.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Propafenone.Approved
LovastatinThe serum concentration of Propafenone can be increased when it is combined with Lovastatin.Approved, Investigational
LucinactantPropafenone may increase the bradycardic activities of Lucinactant.Approved
LuliconazoleThe serum concentration of Propafenone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Propafenone can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Propafenone.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Propafenone.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Propafenone.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Propafenone.Approved
MethadoneThe serum concentration of Methadone can be increased when it is combined with Propafenone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Propafenone.Approved
MethotrimeprazineThe serum concentration of Propafenone can be increased when it is combined with Methotrimeprazine.Approved
MethyldopaMethyldopa may increase the bradycardic activities of Propafenone.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Propafenone.Approved, Vet Approved
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Propafenone.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Propafenone.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Propafenone.Approved
MexiletineThe metabolism of Propafenone can be decreased when combined with Mexiletine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Propafenone.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
MirabegronThe serum concentration of Propafenone can be increased when it is combined with Mirabegron.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Propafenone.Approved
MitotaneThe serum concentration of Propafenone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Propafenone.Approved, Investigational
ModafinilThe serum concentration of Propafenone can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Propafenone.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Propafenone.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Propafenone.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Propafenone.Approved
NafcillinThe serum concentration of Propafenone can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Propafenone.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Propafenone.Approved, Vet Approved
NebivololPropafenone may increase the bradycardic activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Propafenone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Propafenone can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Propafenone can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Nevirapine can be increased when it is combined with Propafenone.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Propafenone.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Propafenone.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Propafenone.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Propafenone.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Propafenone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Propafenone.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Propafenone.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Propafenone.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
OlaparibThe serum concentration of Propafenone can be increased when it is combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Propafenone.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Propafenone.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Propafenone.Approved
OrlistatThe serum concentration of Propafenone can be decreased when it is combined with Orlistat.Approved, Investigational
OsimertinibThe serum concentration of Propafenone can be increased when it is combined with Osimertinib.Approved
OuabainThe serum concentration of Ouabain can be increased when it is combined with Propafenone.Approved
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Propafenone.Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Propafenone.Approved, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Propafenone.Approved, Vet Approved
PalbociclibThe serum concentration of Propafenone can be increased when it is combined with Palbociclib.Approved
PaliperidonePropafenone may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatThe serum concentration of Propafenone can be increased when it is combined with Panobinostat.Approved, Investigational
ParoxetineThe serum concentration of Propafenone can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Propafenone.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Propafenone.Approved
Peginterferon alfa-2bThe serum concentration of Propafenone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Propafenone.Approved, Investigational
PentamidinePentamidine may increase the QTc-prolonging activities of Propafenone.Approved
PentobarbitalThe serum concentration of Propafenone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Propafenone.Approved
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Propafenone.Approved
PhenobarbitalThe serum concentration of Propafenone can be decreased when it is combined with Phenobarbital.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Propafenone.Approved
PhenytoinThe serum concentration of Propafenone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozidePropafenone may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe serum concentration of Pindolol can be increased when it is combined with Propafenone.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Propafenone.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Propafenone.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Propafenone.Approved
Poractant alfaPropafenone may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe serum concentration of Propafenone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Propafenone.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Propafenone.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Propafenone.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Propafenone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Propafenone.Approved, Vet Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Propafenone.Approved
PrimidoneThe serum concentration of Propafenone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamidePropafenone may increase the arrhythmogenic activities of Procainamide.Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Propafenone.Approved, Vet Approved
PromazineThe serum concentration of Promazine can be increased when it is combined with Propafenone.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Propafenone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Propafenone.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Propafenone.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Propafenone.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Propafenone.Approved
QuetiapinePropafenone may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineQuinidine may increase the QTc-prolonging activities of Propafenone.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Propafenone.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Propafenone.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Propafenone.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Propafenone.Approved
RifabutinThe serum concentration of Propafenone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Propafenone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Propafenone can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Propafenone.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Propafenone.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
RitonavirThe serum concentration of Propafenone can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Propafenone.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Propafenone.Approved, Investigational
RolapitantThe serum concentration of Rolapitant can be increased when it is combined with Propafenone.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Propafenone.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Propafenone.Approved, Investigational
RuxolitinibRuxolitinib may increase the bradycardic activities of Propafenone.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Propafenone.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Propafenone.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Propafenone.Approved
SaquinavirSaquinavir may increase the arrhythmogenic activities of Propafenone.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Propafenone.Approved
SertralineSertraline may increase the QTc-prolonging activities of Propafenone.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Propafenone.Approved, Vet Approved
SildenafilThe serum concentration of Propafenone can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Propafenone.Approved
SiltuximabThe serum concentration of Propafenone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Propafenone can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Propafenone.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Propafenone.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Propafenone.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
SotalolThe serum concentration of Sotalol can be increased when it is combined with Propafenone.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Propafenone.Approved
SparteinePropafenone may increase the arrhythmogenic activities of Sparteine.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Propafenone.Experimental
St. John's WortThe serum concentration of Propafenone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Propafenone can be increased when it is combined with Stiripentol.Approved
SufentanilSufentanil may increase the bradycardic activities of Propafenone.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Propafenone.Approved
SulfisoxazoleThe serum concentration of Propafenone can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Propafenone.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Propafenone.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Propafenone.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Propafenone.Approved
TedisamilPropafenone may increase the arrhythmogenic activities of Tedisamil.Investigational
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Propafenone.Approved
TelavancinPropafenone may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe serum concentration of Propafenone can be increased when it is combined with Telithromycin.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Propafenone.Approved
TenofovirThe metabolism of Propafenone can be decreased when combined with Tenofovir.Approved, Investigational
TerbinafineThe serum concentration of Propafenone can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Propafenone.Approved
TeriflunomideThe serum concentration of Propafenone can be decreased when it is combined with Teriflunomide.Approved
TetrabenazinePropafenone may increase the QTc-prolonging activities of Tetrabenazine.Approved
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Propafenone.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Propafenone.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Propafenone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Propafenone.Approved
TiclopidineThe serum concentration of Ticlopidine can be increased when it is combined with Propafenone.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Propafenone.Approved
TipranavirThe serum concentration of Propafenone can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Propafenone.Approved
TocilizumabThe serum concentration of Propafenone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Propafenone.Approved, Investigational
TolterodineTolterodine may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Propafenone.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Propafenone.Approved, Investigational
ToremifenePropafenone may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TranylcypromineThe serum concentration of Tranylcypromine can be increased when it is combined with Propafenone.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Propafenone.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Propafenone.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Propafenone.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Propafenone.Approved, Vet Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Propafenone.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Propafenone.Approved
VandetanibPropafenone may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Propafenone.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Propafenone.Approved
VemurafenibThe serum concentration of Propafenone can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Propafenone.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Propafenone.Approved
VerapamilThe serum concentration of Propafenone can be increased when it is combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Propafenone.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Propafenone.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Propafenone.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Propafenone.Approved
VoriconazoleThe serum concentration of Propafenone can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Propafenone.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Propafenone.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Propafenone.Approved
ZiprasidoneThe serum concentration of Ziprasidone can be increased when it is combined with Propafenone.Approved
ZuclopenthixolPropafenone may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Always take at the same time in regard to meals.
  • Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.
References
Synthesis Reference

Helmut Lietz, “Preparation of propafenone.” U.S. Patent US4474986, issued May, 1974.

US4474986
General ReferencesNot Available
External Links
ATC CodesC01BC03
AHFS Codes
  • 24:04.04.12
PDB EntriesNot Available
FDA labelDownload (91.1 KB)
MSDSDownload (73.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.996
Blood Brain Barrier-0.958
Caco-2 permeable-0.5433
P-glycoprotein substrateSubstrate0.8548
P-glycoprotein inhibitor IInhibitor0.8565
P-glycoprotein inhibitor IIInhibitor0.874
Renal organic cation transporterNon-inhibitor0.7204
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.5499
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.7066
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8931
Ames testNon AMES toxic0.8446
CarcinogenicityNon-carcinogens0.8879
BiodegradationNot ready biodegradable0.803
Rat acute toxicity2.3795 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5383
hERG inhibition (predictor II)Inhibitor0.8915
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral150 mg
TabletOral300 mg
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral225 mg/1
Capsule, extended releaseOral225 1/1
Tablet, coatedOral150 mg/1
Tablet, coatedOral225 mg/1
Tablet, coatedOral300 mg/1
Tablet, film coatedOral300 mg/1
Capsule, extended releaseOral225 mg/1
Capsule, extended releaseOral325 mg/1
Capsule, extended releaseOral425 mg/1
Prices
Unit descriptionCostUnit
Rythmol SR 325 mg 12 Hour Capsule8.9USD capsule
Rythmol SR 425 mg 12 Hour Capsule8.9USD capsule
Rythmol sr 325 mg capsule8.56USD capsule
Rythmol sr 425 mg capsule8.56USD capsule
Rythmol SR 225 mg 12 Hour Capsule7.02USD capsule
Rythmol sr 225 mg capsule6.75USD capsule
Rythmol 225 mg tablet6.2USD tablet
Rythmol 300 mg tablet5.05USD tablet
Rythmol 150 mg tablet3.95USD tablet
Propafenone hcl 300 mg tablet3.03USD tablet
Propafenone hcl 225 mg tablet2.38USD tablet
Rythmol 300 mg Tablet2.09USD tablet
Propafenone hcl 150 mg tablet1.64USD tablet
Rythmol 150 mg Tablet1.18USD tablet
Apo-Propafenone 300 mg Tablet0.79USD tablet
Pms-Propafenone 300 mg Tablet0.79USD tablet
Apo-Propafenone 150 mg Tablet0.45USD tablet
Pms-Propafenone 150 mg Tablet0.45USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5681588 No1994-10-282014-10-28Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySlightly solubleNot Available
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00758 mg/mLALOGPS
logP3.1ALOGPS
logP3.54ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.63ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.56 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity100.21 m3·mol-1ChemAxon
Polarizability39.75 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as chalcones and dihydrochalcones. These are organic compounds containing 1,3-Diphenylpropenone (benzylideneacetophenone), ArCH=CH(=O)Ar,or its derivatives formed by substitution.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassLinear 1,3-diarylpropanoids
Sub ClassChalcones and dihydrochalcones
Direct ParentChalcones and dihydrochalcones
Alternative Parents
Substituents
  • Chalcone or dihydrochalcone
  • Butyrophenone
  • Acetophenone
  • Aryl alkyl ketone
  • Aryl ketone
  • Phenol ether
  • Benzoyl
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Secondary alcohol
  • Ketone
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is respon...
Gene Name:
SCN5A
Uniprot ID:
Q14524
Molecular Weight:
226937.475 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Mergenthaler J, Haverkamp W, Huttenhofer A, Skryabin BV, Musshoff U, Borggrefe M, Speckmann EJ, Breithardt G, Madeja M: Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel. Naunyn Schmiedebergs Arch Pharmacol. 2001 Apr;363(4):472-80. [PubMed:11330342 ]
  2. Arias C, Gonzalez T, Moreno I, Caballero R, Delpon E, Tamargo J, Valenzuela C: Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels. Cardiovasc Res. 2003 Mar;57(3):660-9. [PubMed:12618228 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK: Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol. 1993 Jan;43(1):120-6. [PubMed:8423765 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK: Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol. 1993 Jan;43(1):120-6. [PubMed:8423765 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Schmid D, Ecker G, Kopp S, Hitzler M, Chiba P: Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. Biochem Pharmacol. 1999 Nov 1;58(9):1447-56. [PubMed:10513988 ]
  2. Bachmakov I, Rekersbrink S, Hofmann U, Eichelbaum M, Fromm MF: Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2005 Mar;371(3):195-201. Epub 2005 Apr 15. [PubMed:15900513 ]
  3. Singh P, Paul K: Studies of interactions between uracil-based hybrid molecules and P-glycoprotein--search for multidrug resistance modulators. Bioorg Med Chem. 2006 Nov 1;14(21):7183-6. Epub 2006 Jul 14. [PubMed:16843673 ]
  4. Woodland C, Verjee Z, Giesbrecht E, Koren G, Ito S: The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers. J Pharmacol Exp Ther. 1997 Oct;283(1):39-45. [PubMed:9336306 ]
  5. Tmej C, Chiba P, Huber M, Richter E, Hitzler M, Schaper KJ, Ecker G: A combined Hansch/Free-Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance. Arch Pharm (Weinheim). 1998 Jul-Aug;331(7-8):233-40. [PubMed:9747179 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23